| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10009005 | Annals of Allergy, Asthma & Immunology | 2005 | 5 Pages |
Abstract
Rofecoxib appears to be a safe alternative drug among atopic individuals, antibiotic-hypersensitive individuals, and individuals who experienced adverse cutaneous reactions to more than 1 class of NSAIDs, but it is less safe among chronic urticaria patients. Further investigations that include a larger sample are required to confirm our results especially among chronic urticaria patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Eustachio MD, Maria C. MD, Antonio MD, Alfredo MD,